<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01673295</url>
  </required_header>
  <id_info>
    <org_study_id>P1200_11</org_study_id>
    <nct_id>NCT01673295</nct_id>
  </id_info>
  <brief_title>RING - Rituximab for Lupus Nephritis With Remission as a Goal</brief_title>
  <acronym>RING</acronym>
  <official_title>RING - Rituximab for Lupus Nephritis With Remission as a Goal, an Investigator-initiated Randomized International Open Multicentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frédéric A. Houssiau, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE To test whether Rituximab (RTX) is efficacious to achieve complete renal response
      (CR) in Lupus Nephritis (LN) patients with persistent proteinuria (≥1g/d) despite at least 6
      months of standard of care (SOC).

      STUDY DESIGN Investigator-initiated randomized international open multicentric 104-week
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After screening (week -8), patients enter in a run-in period of 6 weeks during which
      treatment is unchanged. At week -2, if persistent proteinuria is confirmed (uP/C ratio ≥1
      expressed in mg/mg), patients will be randomized in a 1/1 ratio to 1 of 2 treatment groups as
      follows :

      RTX group Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.Control group
      Subjects will not receive RTX infusions. In both arms, azathioprine (AZA) or mycophenolate
      mofetil (MMF) will be continued. If prescribed, prednisolone dose should not be &gt; 10 mg/day.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the percentage of patients achieving renal complete response (CR) at w104.</measure>
    <time_frame>104 weeks</time_frame>
    <description>CR is defined as :
uP/C ratio ≤0.5 (expressed in mg/mg) measured in a 24-h urine collection; and
eGFR &gt;=60ml/min or, if &lt;60ml/min at screening, not fallen by &gt;20% compared to screening; and
no increase of glucocorticoïds (GC) throughout the study (except for two limited courses as per protocol; vide infra); and
no introduction of another immunosuppressant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>RTX group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will not receive RTX infusions and will be followed in standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTX infusions</intervention_name>
    <description>RTX + Standard of Care</description>
    <arm_group_label>RTX group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care only</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All the following inclusion criteria are to be met :

          1. SLE, according to ACR and/or SLICC (Arthritis Rheum 2012; May 2; doi:
             10.1002/art.34473) criteria ;

          2. Age ≥15y (except if local ethics committee imposes ≥18y) ;

          3. ISN/RPS 2003 Class III (A or A/C), IV (A or A/C ; S or G) or V lupus GN confirmed on
             renal biopsy performed within 24 months before screening ;

          4. Having received one out of four following immunosuppressive regimens:

             i): Euro-Lupus (EL) intravenous (IV) cyclophosphamide (CY) (6x 500 mg q2w) followed by
             AZA/MMF for 3 months ; ii): NIH IVCY for 6M (6 monthly pulses) followed by AZA/MMF for
             3 months ; iii): MMF for at least 6 months at a dose of 2g/day (or the maximal
             tolerated dose; iv): AZA for at least 6 months at a dose of 2 mg/kg/day (or the
             maximal toerated dose).

             All patients should be on AZA or MMF at screening. In all regimens, MMF can be
             replaced by enteric-coated mycophenolic acid (eMPA) ;

          5. If on GC, being on maximum 10 mg equivalent prednisolone/d at screening (for at least
             2 weeks) ;

          6. uP/C ratio ≥1 (expressed in mg/mg) measured in a 24-h urine collection, confirmed at
             randomization (w-2) ;

          7. Contraception (any type ; sexual abstinence is an alternative to contraception in
             paediatric patients) ;

          8. Signed informed consent (drafted according to local practice and approved by the local
             ethics committee).

        Exclusion Criteria:

        Any of the following :

          1. Recent or ongoing renal flare defined as either i) : fall in estimated glomerular
             filtration rate (eGFR ; MDRD) ≥25% within 3 month prior to screening or between
             screening and randomization ; or ii) : increase in urine protein by ≥100% to &gt;3.5g/d
             compared to previous assessment ;

          2. 24-h proteinuria decline &gt;50% over previous 6 months ;

          3. Treatment with ≥10 mg equivalent prednisolone/d in the last 2 weeks before screening ;

          4. Pregnancy or breast-feeding ;

          5. Anticipated non-compliance with the protocol ;

          6. History of malignancy (except non-melanoma skin and cervical intraepithelial cancer) ;

          7. Previous treatment with RTX (whenever) and previous treatment with another biologic
             agent within the last 6 months ;

          8. HIV infection ;

          9. Active HBV/HCV/TB infection ;

         10. Severe liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,
             haematologic or psychiatric disturbances, that would contraindicate inclusion in the
             protocol, as judged by the clinician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric A Houssiau, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédéric A Houssiau, MD PHD</last_name>
    <phone>+32 2 7645391</phone>
    <email>frederic.houssiau@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geneviève J Depresseux, Trial Coord</last_name>
    <phone>+32 2 7645395</phone>
    <email>genevieve.depresseux@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric A Houssiau, MD PHD</last_name>
      <phone>+32 2 7645391</phone>
      <email>frederic.houssiau@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Geneviève J Depresseux, Trial Coord</last_name>
      <phone>+32 2 7645395</phone>
      <email>genevieve.depresseux@uclouvain.be</email>
    </contact_backup>
    <investigator>
      <last_name>Frédéric A Houssiau, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2012</study_first_submitted>
  <study_first_submitted_qc>August 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2012</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Frédéric A. Houssiau, MD, PhD</investigator_full_name>
    <investigator_title>Professeur Ordinaire, Chef de Service Clinique</investigator_title>
  </responsible_party>
  <keyword>Lupus Nephritis</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

